- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | H.C. Wainwright initiates First Tracks stock with buy rating | 2 | Investing.com | ||
| 23.04. | JPMorgan initiates First Tracks Biotherapeutics stock at Overweight | 1 | Investing.com | ||
| 22.04. | Barclays initiates First Tracks Biotherapeutics stock at Overweight | 1 | Investing.com | ||
| 21.04. | UBS sieht bei First Tracks Biotherapeutics über 350 % Kurspotenzial | 5 | Investing.com Deutsch | ||
| 21.04. | UBS initiates First Tracks Biotherapeutics stock with buy rating | 1 | Investing.com | ||
| 20.04. | First Tracks Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.04. | AnaptysBio rises after completing First Tracks spinoff | 6 | Seeking Alpha | ||
| 20.04. | AnaptysBio completes spin-off of First Tracks Biotherapeutics | 5 | Investing.com | ||
| FIRST TRACKS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.04. | First Tracks Biotherapeutics Inc: First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases | 3 | GlobeNewswire (USA) | ||
| 20.04. | AnaptysBio, Inc.: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | 390 | GlobeNewswire (Europe) | Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately... ► Artikel lesen | |
| 17.04. | First Tracks Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 03.04. | AnaptysBio gliedert First Tracks Biotherapeutics aus: Handel an der NASDAQ startet am 20. April | 5 | Investing.com Deutsch | ||
| 27.03. | AnaptysBio spinoff First Tracks Bio raises $80M in placement | 1 | Investing.com | ||
| 27.03. | Anaptys to spin-off First Tracks BioTherapeutics, announces $100M buyback | 3 | Seeking Alpha | ||
| 27.03. | AnaptysBio, Inc.: Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics | 484 | GlobeNewswire (Europe) | Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-marketStockholders will receive one share of First Tracks Bio common stock for every one... ► Artikel lesen | |
| 27.03. | AnaptysBio, Inc.: First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement | 342 | GlobeNewswire (Europe) | Inclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,035 | +1,84 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,040 | -25,29 % | Summit Therapeutics Inc. - 10-Q, Quarterly Report | ||
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| EVOTEC | 5,240 | +4,70 % | Evotec kassiert Millionen-Förderung: KI und neue Therapien im Fokus - unterschätzter Kurstreiber? | Evotec SE meldet einen strategisch wichtigen Erfolg: Gleich zwei neue Förderzusagen der Gates Foundation stärken die Forschung im Bereich Tuberkulose. Insgesamt fließen rund 9,9 Millionen US-Dollar... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 329,55 | +3,45 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| ERASCA | 10,390 | -2,35 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,340 | +2,15 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| MINERALYS THERAPEUTICS | 28,660 | +7,58 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| PHATHOM PHARMACEUTICALS | 11,750 | +5,38 % | Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | ~1.35 million total VOQUEZNA prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,050 | -2,23 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| BEAM THERAPEUTICS | 30,980 | +2,21 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| LAKEWOOD-AMEDEX BIOTHERAPEUTICS | 3,490 | +33,72 % | Lakewood-Amedex reports resistance data for diabetic ulcer drug | ||
| RELAY THERAPEUTICS | 12,860 | -0,73 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 63,07 | -0,93 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | ||
| COGENT BIOSCIENCES | 36,175 | +1,19 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen |
FIRST TRACKS BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 20,800 Euro und damit -11,07 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FIRST TRACKS BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.